Novartis Ag (NVS) Interest Expenses (2009 - 2026)

Novartis Ag's Interest Expenses history runs 18 years deep, the most recent figure standing at -$343.0 million for Q1 2026.

• In Q1 2026, Interest Expenses fell 27.04% year-over-year to -$343.0 million; the TTM figure through Mar 2026 stood at -$1.2 billion (down 15.36% YoY), while the FY2025 annual figure was $1.1 billion, up 13.72% from the prior year.
• Interest Expenses came in at -$343.0 million for Q1 2026 at Novartis Ag, down from -$304.0 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of -$200.0 million in Q1 2023 to a low of -$403.0 million in Q2 2022.
• A 5-year average of -$256.8 million and a median of -$246.0 million in 2024 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses soared 46.4% in 2023 and dropped 27.04% in 2026, its largest moves.
• Novartis Ag's Interest Expenses stood at -$207.0 million in 2022, then retreated by 4.83% to -$217.0 million in 2023, then slipped by 26.73% to -$275.0 million in 2024, then fell by 10.55% to -$304.0 million in 2025, then fell by 12.83% to -$343.0 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered -$343.0 million, -$304.0 million, and -$281.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison